ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 589,39
-0,57%
Dow Jones
40 211,72
0,53%
DAX
18 499,15
-0,54%
Brent Oil
83,675
-0,79%
Bitcoin
63 115,10
-2,68%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
08/09/202114h00Business WireLate-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 2021 Showed AJOVY® (fremanezumab-vfrm) Injection Reduced More Monthly Migraine Days in a Network Meta-Analysis Study with Atogepant and RimegepantNYSE:TEVATeva Pharmaceutical Industries Ltd
31/08/202123h11Dow Jones NewsTeva, MedinCell Say FDA Accepts NDA for Schizophrenia TreatmentNYSE:TEVATeva Pharmaceutical Industries Ltd
31/08/202122h15Business WireTeva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with SchizophreniaNYSE:TEVATeva Pharmaceutical Industries Ltd
31/08/202122h15Business WireTeva et MedinCell annoncent l’acceptation par la FDA du dossier de demande d’approbation du traitement TV46000/mdc-IRM pour les patients atteints de schizophrénieNYSE:TEVATeva Pharmaceutical Industries Ltd
30/08/202114h00Business WireShowcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache...NYSE:TEVATeva Pharmaceutical Industries Ltd
27/08/202112h11Edgar (US Regulatory)Current Report Filing (8-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
20/08/202114h00Business WireTeva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) Tablets in Adult Patients with Tardive DyskinesiaNYSE:TEVATeva Pharmaceutical Industries Ltd
19/08/202122h04Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NYSE:TEVATeva Pharmaceutical Industries Ltd
12/08/202122h04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
28/07/202122h11Edgar (US Regulatory)Quarterly Report (10-q)NYSE:TEVATeva Pharmaceutical Industries Ltd
28/07/202113h30Business WireTeva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent AnalysisNYSE:TEVATeva Pharmaceutical Industries Ltd
28/07/202113h00Business WireTeva Reports Second Quarter 2021 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
21/07/202114h00Business WireTeva Announces Changes to Executive Management TeamNYSE:TEVATeva Pharmaceutical Industries Ltd
01/07/202118h14Business WireTeva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 28, 2021NYSE:TEVATeva Pharmaceutical Industries Ltd
30/06/202111h09TipRanksTeva, Bioeq Partner to Sell Lucentis BiosimilarNYSE:TEVATeva Pharmaceutical Industries Ltd
28/06/202119h39Business WireTeva und Bioeq geben Vertriebspartnerschaft für Biosimilar bekanntNYSE:TEVATeva Pharmaceutical Industries Ltd
28/06/202117h46Business WireTeva et Bioeq annoncent un partenariat commercial dans le domaine des biosimilairesNYSE:TEVATeva Pharmaceutical Industries Ltd
28/06/202114h00Business WireTeva and Bioeq Announce Commercial Partnership for BiosimilarNYSE:TEVATeva Pharmaceutical Industries Ltd
23/06/202114h12Business WireTeva Announces Ministry of Health, Labour & Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Tre...NYSE:TEVATeva Pharmaceutical Industries Ltd
23/06/202108h58Business WireNouvelles données relatives à l'innocuité du traitement par COPAXONE® (acétate de glatiramère) chez les mères allaitan...NYSE:TEVATeva Pharmaceutical Industries Ltd
22/06/202123h18Business WireTeva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to T...NYSE:TEVATeva Pharmaceutical Industries Ltd
22/06/202116h36Business WireNeue Sicherheitsdaten zur Behandlung von stillenden Müttern mit COPAXONE® (Glatirameracetat), die mit schubförmig verlaufe...NYSE:TEVATeva Pharmaceutical Industries Ltd
22/06/202110h17Business WireTeva présente de nouvelles données lors du 7e congrès de l’Académie européenne de neurologie, suggérant que des facte...NYSE:TEVATeva Pharmaceutical Industries Ltd
22/06/202108h30Business WireNew Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple S...NYSE:TEVATeva Pharmaceutical Industries Ltd
22/06/202107h24Business WireTeva präsentiert neue Daten auf dem 7. Kongress der European Academy of Neurology, die sozioökonomische Faktoren mit einer ...NYSE:TEVATeva Pharmaceutical Industries Ltd
22/06/202104h55Business WireDe nouvelles données étayant le profil d’innocuité et d’efficacité d’AJOVY® (frémanezumab) partagées lors du 7e ...NYSE:TEVATeva Pharmaceutical Industries Ltd
22/06/202104h54Business WireNeue Daten, die das Sicherheits- und Wirksamkeitsprofil von AJOVY® (Fremanezumab) stützen, werden auf dem 7. Kongress der E...NYSE:TEVATeva Pharmaceutical Industries Ltd
21/06/202114h01Business WireNew Data Supporting the Safety & Efficacy Profile of AJOVY® (fremanezumab) Shared at 7th European Academy of Neurology Congr...NYSE:TEVATeva Pharmaceutical Industries Ltd
21/06/202114h01Business WireTeva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Factors May Contribute to the ...NYSE:TEVATeva Pharmaceutical Industries Ltd
16/06/202113h36Business WireTeva Announces the U.S. Launch of its Generic Version of SOOLANTRA® (ivermectin) Cream, 1% for Once Daily Treatment of RosaceaNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

BIT
P25390
NLBNPIT25390 20240920 1050
EU
FRSG00014F70
SG Issuer Sgi Zc Dec28 Eur
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés